Skip to contentA
aTYR PHARMA INC
A
ATYRaTYR PHARMA INC Q2 2019 · 10-Q
Revenue$94.00K$94.00Kno prior Q2 2018 on file Net Income-$5.85M-$5.85MN/M vs Q2 2018 EPS Diluted-$1.80-$1.80N/M vs Q2 2018 Operating Income-$5,641,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
aTYR PHARMA INC · CIK 1339970 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$4,821,000N/M Margins · derivedOperating margin-6001.1%
Net margin-6221.3%
ended Jun 30, 2019 · filed Aug 14, 2019 · 45 d after period end